坦索罗辛联合舍尼亭治疗严重尿频相关性睡眠障碍的疗效观察  

Tamsulosin combined with tolterodine tartrate in the treatment of patients with somnipathy pertained to severe nocturia

作　　者：郭咏萍[1] 蒋晓江[1] 周红杰[1] 姚国恩[1] 王景周[1] 李玮[1] 张远凤[1] 

机构地区：[1]第三军医大学大坪医院野战外科研究神经内三科,重庆400042

出　　处：《重庆医学》2009年第10期1168-1170,共3页Chongqing medicine

摘　　要：目的探讨坦索罗辛联合舍尼亭治疗尿频相关性睡眠障碍的疗效。方法对严重夜尿所致睡眠障碍73例患者在常规导眠药物治疗基础上,联合服用坦索罗辛、舍尼亭治疗8周。症状改善评估采用尿频综合征症状评分(USS)、匹兹堡睡眠质量指数(PSQI)、生活质量评分(QOL)为主要疗效指标,观察治疗效果。结果治疗后患者睡眠质量及生活质量改善,PSQI、USS、QOL分值明显降低,差异有统计学意义(P<0.01)。结论坦索罗辛(0.4mg/d)联合舍尼亭可提高夜尿性睡眠障碍患者的睡眠质量。Objective To evaluate inhibitors of αlA receptor （tamsulosin） and toherodine tartrate in the treatment of patients with somnipathy pertained to nocturia （SPN）. Methods Seventy-three patients suffering from SPN were treated with tamsulosin and tolterodine tartrate for 8 weeks besides accepting sleeping pill. The effects were evaluated mainly with urethral syndrome score （USS） ,Pittsburgh sleep quality index （PSQI） and quality of life（QOL）. Results With the utilization of the tamsulosin and tolterodine,the PSQI, USS and QOL coefficient decreased significantly after 8 weeks treatment. An improvement in nocturia, increase of the hours of undisturbed sleep and improvement in the QOL were observed. There was statistically significant difference of urodynamics data,USS and QOL before and after treatment （P〈0.05 or P〈0.01）. Conclusion Tamsulosin and tolterodine tartrate could meliorate the sleep quality for patients with somnipathy pertained to nocturia.

关 键 词：睡眠障碍 夜尿 坦索罗辛 舍尼亭 

分 类 号：R740[医药卫生—神经病学与精神病学]